-
Science & technology
Science & technology
Novavax creates transformational vaccines that help address some of the world’s most pressing infectious diseases.
- Overview
- Our pipeline
- Matrix-M™ adjuvant
- Recombinant, protein-based nanoparticle vaccine
- Global vaccine approval/authorization map
COVID-19 UPDATESNovavax has demonstrated its ability to quickly produce viable vaccine candidates for emerging infectious diseases such as COVID-19.
-
Who we are
Who we are
We are a biotechnology company committed to help address serious infectious disease globally through the discovery, development, and delivery of innovative vaccines to patients around the world.
Build your future with usJoin other passionately curious people who are bringing innovative vaccines to the world
-
Insights
Insights
Novavax is committed to accelerating the development of new and promising vaccines by building on years of study and experience.
A NEW ERA OF VACCINES
The Novavax COVID-19 Vaccine, Adjuvanted is now available in
the U.S. under Emergency Use Authorization for primary vaccination
for individuals 12+, and as a first booster dose for adults
See conditions of use
Latest press release on vaccine candidates

COVID-19 vaccine research updates
Novavax COVID-19 vaccine (recombinant, adjuvanted) is now conditionally authorized in several regions

Novavax information for:
NEWS & MEDIA
Current Protocol for Phase 3 Clinical Trial of NVX-CoV2373 in the U.S. and Mexico

Novavax first quarter 2022 financial results
Browse the calendar and sign up to view investor-related events and announcements. Webcasts and presentations that have been archived are also available by viewing historical event details.

Latest quarterly earnings
Latest investor presentation
2021 annual report
Explore current opportunities in:
39
jobs available
at Novavax
